Tris Pharma Initiates Pivotal P-III Study to Evaluate Cebranopadol for Moderate-to-Severe Acute Pain
Shots:
- Tris Pharma reported the initiation of a pivotal P-III (ALLEVIATE-1 & ALLEVIATE-2) study assessing the efficacy & safety of cebranopadol (TRN-228) for moderate-to-severe acute pain patients (n=500)
- ALLEVIATE-1 (n=300; US 6 clinical study) & ALLEVIATE-2 (n=240; US 8 clinical study) is a P-III study, a randomized, double-blind, placebo-controlled trial, that 1EP assessing the analgesic efficacy of cebranopadol vs PBO in treating moderate-to-severe pain following full abdominoplasty & bunionectomy as measured by pain intensity assessments respectively
- 2EP includes evaluating the safety & tolerability efficacy of cebranopadol vs oxycodone (ALLEVIATE 1 & 2) and efficacy using rescue medication ((ALLEVIATE 2)
Ref: Tris Pharma | Image: Tris Pharma
Related News:- Tris Pharma’s Onyda XR Gains the US FDA’s Approval for the Treatment of Attention Deficit Hyperactivity Disorder (ADHD)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
